Liquidia (LQDA) Other Non-Current Assets (2019 - 2026)
Liquidia's (LQDA) quarterly Other Non-Current Assets came in at $3.5 million in Q1 2026, down 77.45% year-on-year from $15.5 million in Q1 2025, and little changed quarter-over-quarter from $3.5 million in Q4 2025.
Liquidia (LQDA) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Liquidia's Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $3.5 million for Q1 2026.
- On a quarterly basis, Other Non-Current Assets fell 77.45% year-over-year to $3.5 million in Q1 2026; TTM through Mar 2026 was $3.5 million, a 77.45% decrease from a year earlier, with the FY2025 full-year figure at $3.5 million, down 67.91% from the prior year.
- Other Non-Current Assets held at $3.5 million in Q1 2026 per LQDA's latest filing, from $3.5 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $15.5 million in Q1 2025 and bottomed at $224000.0 in Q1 2024.
- The 5-year median for Other Non-Current Assets is $307000.0 (2022), against an average of $3.0 million.
- Across the five-year window, Other Non-Current Assets jumped 6838.39% in 2025 and sank 77.45% in 2026, its largest moves.
- Year by year, Other Non-Current Assets stood at $307000.0 in 2022, then declined by 6.51% to $287000.0 in 2023, then surged by 3704.18% to $10.9 million in 2024, then plunged by 67.91% to $3.5 million in 2025, then changed by 0.0% to $3.5 million in 2026.
- Per Business Quant, the three latest LQDA Other Non-Current Assets figures stand at $3.5 million (Q1 2026), $3.5 million (Q4 2025), and $3.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn | 3.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.50 Mn |
| Dec 31, 2025 | 3.50 Mn |
| Sep 30, 2025 | 3.50 Mn |
| Jun 30, 2025 | 3.50 Mn |
| Mar 31, 2025 | 15.54 Mn |
| Dec 31, 2024 | 10.92 Mn |
| Sep 30, 2024 | 7.76 Mn |
| Jun 30, 2024 | 224,000.00 |
| Mar 31, 2024 | 224,000.00 |
| Dec 31, 2023 | 287,000.00 |
| Sep 30, 2023 | 287,000.00 |
| Jun 30, 2023 | 260,000.00 |
| Mar 31, 2023 | 307,000.00 |
| Dec 31, 2022 | 307,000.00 |
| Sep 30, 2022 | 307,000.00 |
| Jun 30, 2022 | 307,000.00 |
| Mar 31, 2022 | 307,000.00 |
| Dec 31, 2021 | 311,000.00 |
| Sep 30, 2021 | 312,925.00 |
| Jun 30, 2021 | 318,331.00 |